Rare lephants
Screener

BIOCRYST PHARMACEUTICALS, INC.

BCRX ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — BioCryst Pharmaceuticals, Inc.

Total Moat Score 10 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 4 / 5 ORLADEYO is a patented, FDA-approved therapy with multi-year regulatory exclusivity and a structure-guided drug discovery platform generating further IP.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 Biotech drug development and commercialization carries no inherent cost advantage over similarly-resourced pharma competitors.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 3 / 5 As a rare-disease therapy with few alternatives, ORLADEYO commands premium specialty-drug pricing, though payer pushback and new oral competitor sebetralstat will test this.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 Pharmaceutical sales have no network effect dynamics.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 2 / 5 Patients stabilized on a working HAE prophylactic regimen are often reluctant to switch, but rival therapies actively court switches and roughly half of new ORLADEYO patients themselves switched from other drugs.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 The HAE prophylaxis market is a small, specialized rare-disease niche, but it is now attracting multiple well-funded competitors (Takeda, CSL Behring, KalVista, Pharvaris) rather than staying naturally limited to one player.